Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at European Society of Cardiology Congress 2023
Evidence that 13-M, a unique small molecule disruptor of adrenergic SERCA2 activity reduces infarct size and preserves cardiac function
Oslo, Norway – 29 August 2023 – Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today presented exciting preclinical data showcasing its novel therapeutic strategy targeting the SERCA2 complex to protect heart tissue from ischemia-reperfusion injury at the European Society of Cardiology Congress 2023, the world’s largest cardiology congress, in Amsterdam, The Netherlands, 25-28 August 2023.
